Table 4.
Classes and specific drugs suspected to be responsible for SJS and TEN reported to the NPC between 2004 and 2017.
| Class and specific drug name | SJS | TEN | Total for SJS and TEN n (%) |
|---|---|---|---|
| Antiretroviral | |||
| Nevirapine | 166 | 8 | 174 (40.7) |
| Evafirenz | 9 | 1 | 10 (2.3) |
| Antibiotic | |||
| Cotrimoxazole | 136 | 7 | 143 (33.5) |
| Ciprofloxacin | 3 | 1 | 4 (0.9) |
| Erythromycin | 3 | 0 | 3 (0.7) |
| Crystalline- penicillin injection | 2 | 0 | 2 (0.5) |
| Cephalexin | 1 | 0 | 1 (0.2) |
| Ampicillin-cloxacillin | 1 | 0 | 1 (0.2) |
| Amoxicillin-clavulanate | 1 | 0 | 1 (0.2) |
| Doxycycline | 1 | 0 | 1 (0.2) |
| Cefixime | 1 | 0 | 1 (0.2) |
| Ceftriaxone injection | 1 | 0 | 1 (0.2) |
| Ceftazidime injection | 0 | 1 | 1 (0.2) |
| Levofloxacin | 0 | 1 | 1 (0.2) |
| Antimalarial | |||
| Sulfadoxime-pyrimethamine | 21 | 7 | 28 (6.6) |
| Artemether-lumefantrine | 6 | 4 | 10 (2.3) |
| Dihydroartemisinin-piperaquin | 2 | 0 | 2 (0.5) |
| Arteether | 2 | 0 | 2 (0.5) |
| Amodiaquine | 2 | 0 | 2 (0.5) |
| Artesunate | 2 | 0 | 2 (0.5) |
| Chloroquine | 1 | 1 | 2 (0.5) |
| Proguanil | 1 | 0 | 1 (0.5) |
| Camoquin | 0 | 1 | 1 (0.2) |
| Antiepileptic | |||
| Carbamazepine | 4 | 3 | 7 (1.6) |
| Phenytoin | 2 | 1 | 3 (0.7) |
| Analgesic/antipyretic | |||
| Piroxican | 2 | 0 | 2 (0.5) |
| Acetaminophen | 2 | 0 | 2 (0.5) |
| Dipyrone | 1 | 0 | 1 (0.2) |
| Antituberculosis | |||
| Rifampicin | 4 | 0 | 4 (0.9) |
| Antiulcer | |||
| Cimetidine | 1 | 0 | 1 (0.2) |
| Antipsychotic | |||
| Olanzapine | 1 | 0 | 1 (0.2) |
| Chlorpromazine | 0 | 2 | 2 (0.5) |
| Herbal medicine | |||
| Herbal product or concoction | 5 | 1 | 6 (1.4) |
| Antiparasitic | |||
| Ivermectin | 1 | 0 | 1 (0.2) |
| Antilipidemic | |||
| Artovastatin | 1 | 0 | 1 (0.2) |
| Vaccine | |||
| Tetanus toxoid | 0 | 2 | 2 (0.5) |
| TOTAL | 386 (90.4%) | 41 (9.6%) | 427 (100.0%) |
NPC, National Pharmacovigilance Center; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.